Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 24Carcinoma, Renal Cell 15Carcinoma, Non-Small-Cell Lung 15Neoplasm Metastasis 12Urinary Bladder Neoplasms 6Sarcoma 6Prostatic Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Neoplasms 5Kidney Neoplasms 5Ovarian Neoplasms 4Glioblastoma 4Carcinoma, Transitional Cell 4Uveal Melanoma 3Small Cell Lung Carcinoma 3Myelodysplastic Syndromes 3Mesothelioma 3Histiocytoma, Malignant Fibrous 3Colorectal Neoplasms 3Chordoma 3Carcinoma, Neuroendocrine 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Brain Neoplasms 3Urogenital Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2

Interventions

Cyclophosphamide 7fludarabine 6Whole-Body Irradiation 6Tacrolimus 6Mycophenolic Acid 6ruxolitinib 5fludarabine phosphate 5Melphalan 5venetoclax 4Peripheral Blood Stem Cell Transplantation 4itacitinib 3Specimen Handling 3Sirolimus 3Granulocyte Colony-Stimulating Factor 3Cytarabine 3Biopsy 3Azacitidine 3navitoclax 2luspatercept 2Etoposide 2Daunorubicin 2Busulfan 2Antilymphocyte Serum 2thymoglobulin 1selinexor 1quizartinib 1pomalidomide 1plerixafor 1pevonedistat 1parsaclisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Myeloproliferative Disorders × Ipilimumab × Clear all
NCT03912064 2026-01-05

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
25 enrolled 17 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡